Rozanolixizumab, sold under the brand name Rystiggo, is a monoclonal antibody used for the treatment of myasthenia gravis. Rozanolixizumab is a humanized...
9 KB (497 words) - 03:01, 17 April 2025
Hytrulo) was approved for medical use in the United States in June 2023. Rozanolixizumab (Rystiggo) was approved for medical use in the United States in June...
83 KB (8,943 words) - 12:27, 22 May 2025
L04AG13 Teprotumumab L04AG14 Ublituximab L04AG15 Divozilimab L04AG16 Rozanolixizumab L04AG17 Seniprutug L04AH01 Sirolimus L04AH02 Everolimus L04AJ01 Eculizumab...
3 KB (377 words) - 04:18, 23 December 2024
Langdon G, Tran D, Bari M, et al. (November 2017). "The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study"...
36 KB (4,071 words) - 23:49, 15 May 2025
Retrieved 2 February 2020. "UCB announces U.S. FDA approval of Rystiggo (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis"...
141 KB (4,321 words) - 00:07, 11 May 2025
Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab...
38 KB (4,316 words) - 01:22, 4 February 2025
Pegcetacoplan Pirfenidone Ponesimod Ravulizumab Risankizumab Ritlecitinib Rozanolixizumab Sarilumab Satralizumab Siltuximab Siponimod Sirukumab Spesolimab Sutimlimab...
38 KB (2,656 words) - 20:26, 6 November 2024
Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab...
2 KB (87 words) - 01:28, 30 May 2023